Key result
Combining hydroxyurea and etoposide causes dose-limiting myelosuppression.
Why the study?
What is the in vitro interaction and the maximum tolerated dose of combined hydroxyurea and etoposide in a phase I clinical trial?
Population
L1210 murine leukemia cells and 19 patients in a phase I clinical trial
Comparison
Combination of hydroxyurea and etoposide at fixed molar ratio or dose levels
Design
In vitro synergy study and phase I clinical trial
Authors
Loading...
May inform optimized dosing for hydroxyurea-etoposide combinations; hypothesis-generating for clinical translation.
What is the in vitro interaction and the maximum tolerated dose of combined hydroxyurea and etoposide in a phase I clinical trial?
The combination of hydroxyurea and etoposide demonstrates synergy at high doses in vitro and establishes a recommended dosing regimen for phase II trials based on myelosuppression as the dose-limiting toxicity.
Ratain et al. (1988) studied this question. Hydroxyurea and Etoposide was evaluated on Dose-limiting toxic effect. In a phase I clinical trial of 19 patients, the combination of hydroxyurea and etoposide resulted in dose-limiting myelosuppression.